ClinicalTrials.gg
Not yet recruitingNCT06442631Updated Nov 18, 2026

MyStroke for Stroke Survivors and Caregivers

An interventional study of MyStroke in Stroke, Acute and Ischemic Stroke, Acute, sponsored by University of Pennsylvania. Not yet recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionIschemic StrokeRegistry: StrokeReclassifiedWhy we changed it
Registry
Stroke — the first condition term the registry derived for this study.
ClinicalTrials.gg
Ischemic Stroke
Why
  1. The study's listed conditions name Ischemic Stroke, a narrower term within Stroke.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Pennsylvania · Not applicable, Interventional, and Treatment

How we know

Updated Nov 18, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
690
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.

Planned enrollment
39th of 364
690 · median 65
Started
2026
with 35 others
No phase
183 of 480
51 open now
Primary completion
2029-11
later than 128 of 144 live
Registered
413th of 480
by date
Lead sponsor
8 of 480
University of Pennsylvania

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 39th largest by planned enrollment of the 364 interventional ones that give a count, is one of 36 that started in 2026, is one of 183 with no phase, reaches primary completion later than 128 of the 144 other live ones, and was the 413th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

The goal of this multicenter randomized trial is to evaluate the impact of a personalized video-based stroke education platform on patient-centered and health system-centered outcomes. The main questions this study aims to address are:

  1. Does a personalized, video-based educational platform improve stroke knowledge?
  2. Does a personalized, video-based educational platform reduce post-discharge health system utilization?
  3. Do different strategies of nudging improve engagement with educational material after hospital discharge?

In order to determine the effect of this personalized stroke education strategy, researchers will compare subjects who receive standard stroke education with those who receive the personalized stroke education platform in addition to standard standard education. Patient knowledge will be assessed 90-days after discharge. Study participants will include both stroke patients and caregivers, who will:

  1. Receive standard education during the stroke hospitalization
  2. Complete a survey on the day of hospital discharge to assess their baseline knowledge.
  3. Half of the subjects will be randomly assigned to also receive access to the personalized stroke education platform on the day of discharge.
  4. All subjects will complete two follow-up study visits (7 and 90 days after discharge) in order to complete surveys.
Read the detailed description

Stroke education represents a unique opportunity to empower stroke survivors (and caregivers) to promote self-management, augment adherence, and reduce post-stroke healthcare utilization. Despite being a key quality metric for stroke centers, most patient and caregiver education is poorly retained and a common source of dissatisfaction. In fact, most survivors are unaware of the cause of their stroke, their modifiable risk factors, and how to properly respond to future stroke symptoms. Although there is no gold standard, most centers rely on a combination of bedside verbal communication and standardized printed materials. Prior work has clarified that effective and durable educational interventions benefit from engaging content, personalization, accessibility, and low cost/burden. Retention is very poor during the stroke hospitalization, but this can be overcome by promoting ongoing engagement after discharge.

To that end, our group developed a web-based educational platform (MyStroke) that leverages the electronic health record to personalize video-based educational content for each stroke survivor. Simple but engaging videos are curated to address each patient's stroke etiology, individualized risk factors, prescribed stroke prevention medications, and post-stroke lifestyle issues. This approach transforms point-of-care stroke education, and integrated nudges reveal opportunities for re-education and re-engagement after hospital discharge to achieve a durable impact. In a recent single-center pilot trial, MyStroke improved patient and caregiver satisfaction and improved key elements of stroke knowledge. The objective of this proposal is to build upon our encouraging preliminary experience and conduct a multicenter randomized trial to evaluate the impact of MyStroke on both patient-centered (stroke knowledge, self-efficacy, satisfaction, quality of life) and health system-centered outcomes (medication adherence and health system utilization).

Electronic nudges will leverage principles of behavioral economics (i.e. enhanced nudges) to promote ongoing engagement. Our preliminary data indicate that even bland nudges promote engagement, but here we propose to use both bland nudges and enhanced nudges, such that platform analytics will compare the influence of different nudge types. Use of technology in this context stands to bridge geographic distances, connect stakeholders, and increase access to information, but it important to recognize the potential to exacerbate inequities for elderly patients and those with limited access to technology. Issues of digital inclusivity will be evaluated to reveal opportunities for platform improvement. The MyStroke platform offers a scalable solution stroke education which imposes no burden on the clinical team due to its reliance on a limited number of input fields which can be harvested from the electronic health record to individualized content for each patient.

03

Conditions studied

  • Stroke, Acute
  • Ischemic Stroke, Acute

Browse trials for

Keywords

  • stroke education
  • ischemic stroke
  • stroke knowledge
04

In context

Ischemic Stroke Reclassified

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

This study's planned enrollment of 690 is above the median of 120 across 1,788 interventional studies indexed under Ischemic Stroke.

Browse Ischemic Stroke studies →

Lead sponsor

University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.

Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.

Compared within Ischemic Stroke, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Stroke. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years old
  • Admitted to hospital with clinical diagnosis of acute ischemic stroke (imaging confirmation not required)
  • Stroke symptom onset within 30 days of enrollment
  • Being discharged to either home or an acute rehabilitation facility
  • Access to internet enabled device (smartphone, tablet, computer)
  • Fluent in either English or Spanish (does not need to be native or primary language)
  • Willingness and ability to sign

Exclusion criteria

Exclusion Criteria:

  • Severe aphasia (score of ≥2 on NIHSS item 9)
  • Ischemic stroke that is attributed to a surgical procedure
  • Resides in a skilled nursing facility prior to admission
  • Being discharged to skilled nursing facility or long-term acute care facility
  • Unwillingness or inability to participate in remote/virtual study visits
  • A terminal or advanced condition that raises the possibility the subject may not survive 90 days
  • Any other illness or condition that the investigator feels would pose a hazard to the subject from participation in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
690 participants (estimated)

Study arms

  • No intervention
    Standard stroke education

    Participants in this arm of the study will receive institutional standard stroke education during the course of the hospitalization, standardized across the 5 participating sites. Standard education consists of non-standardized verbal bedside education by the care team, a standardized stroke educational booklet, and standardized verbal instructions by the bedside nurse addressing stroke risk factors and medications.

  • Experimental
    MyStroke + standard stroke education

    Participants in this arm of the study will receive institutional standard stroke education in addition to access to MyStroke, a personalized video-based education platform. Each participant will receive their personalized page via email or SMS, as per their preference, and they will receive automated nudges to visit educational material after hospital discharge.

    Behavioral: MyStroke

Interventions

  • BehavioralMyStroke

    MyStroke is a video-based educational platform that curates brief educational videos to inform patients and caregivers about key aspects of their stroke. Upon registering a user, information regarding the patient's stroke etiology, relevant stroke risk factors, and stroke prevention medications are used to populate educational content that is relevant to the individual. Users receive automated nudges to revisit MyStroke after hospital discharge on day 1, 3, 5, 7, and weekly thereafter.

07

What researchers measure

Primary outcomes

  1. The Stroke Patient Education Retention (SPER) survey

    Total score from the 5-question SPER (scale 0-10; higher score reflects better knowledge)

    Time frame: 90 days

Secondary outcomes

  1. Patient satisfaction with stroke education

    5-point Likert-scale (Q: I am satisfied with the quality of my stroke education; Answers range from strongly disagree to strongly agree)

    Time frame: 90 days

  2. Stroke etiology awareness

    The proportion of patients who correctly identify their stroke etiology (multiple choice)

    Time frame: 90 days

  3. Stroke risk factor awareness

    The proportion of patients who correctly identify at least one of their vascular risk factors (select all that apply)

    Time frame: 90 days

  4. Antithrombotic medication awareness

    The proportion of patients who correctly identify all prescribed antithrombotic medications (free response)

    Time frame: 90 days

  5. Stroke Self-Efficacy Questionnaire (SSEQ)

    Total score from the 13 item questionnaire (each item scored 0-10; total score 0-130; higher scores represent higher levels of self-efficacy)

    Time frame: 90 days

  6. EuroQoL EQ-5D-5L

    A standardized measure of health-related quality of life across 5 domains. Each domain is scored using a 5-point ordinal scale (1-5), and the Level Sum Score (LSS) is calculated as the sum of the 5 scores (LSS range is 5-25, lower scores represent higher quality of life).

    Time frame: 90 days

  7. Medication adherence

    This will be assessed based on pharmacy record review to quantify the Proportion of Days Covered (PDC). PDC is calculated by dividing the number of days with medications available by the total number of days in question (scored between 0 - 1; higher numbers represent more favorable adherence)

    Time frame: 90 days

  8. Emergency Department utilization

    The number of Emergency Room visits will be summed in the first 90 days following hospital discharge

    Time frame: 90 days

  9. Urgent outpatient visits

    The number of urgent outpatient visits with primary care and neurologist will be summed in the first 90 days following hospital discharge

    Time frame: 90 days

  10. Outpatient provider communication

    The number of communications with primary care or neurology providers via telephone or provider communication apps will be summed in the first 90 days following hospital discharge

    Time frame: 90 days

Other outcomes

  1. The Stroke Patient Education Retention (SPER) survey (7 days)

    Total score from the 5-question SPER (scale 0-10; higher score reflects better knowledge)

    Time frame: 7 days

  2. Patient satisfaction with stroke education (7 days)

    5-point Likert-scale (Q: I am satisfied with the quality of my stroke education; Answers range from strongly disagree to strongly agree)

    Time frame: 7 days

  3. Stroke etiology awareness (7 days)

    The proportion of patients who correctly identify their stroke etiology (multiple choice)

    Time frame: 7 days

  4. Stroke risk factor awareness (7 days)

    The proportion of patients who correctly identify at least one of their vascular risk factors (select all that apply)

    Time frame: 7 days

  5. Antithrombotic medication awareness (7 days)

    The proportion of patients who correctly identify all prescribed antithrombotic medications (free response)

    Time frame: 7 days

  6. Stroke Self-Efficacy Questionnaire (SSEQ) (7 days)

    Total score from the 13 item questionnaire (each item scored 0-10; total score 0-130; higher scores represent higher levels of self-efficacy)

    Time frame: 7 days

  7. EuroQoL EQ-5D-5L (7 days)

    A standardized measure of health-related quality of life across 5 domains. Each domain is scored using a 5-point ordinal scale (1-5), and the Level Sum Score (LSS) is calculated as the sum of the 5 scores (LSS range is 5-25, lower scores represent higher quality of life).

    Time frame: 7 days

08

Study locations

5 sites
09

References and documents

Individual participant data

Plan to share: Yes — Once a manuscript describing such data is accepted for publication, the deidentified dataset contributing to the publication will be shared publicly using the figshare repository (figshare.com). The availability of shared derived data will be described in publications and presentation.

Supporting information: Study protocol, Statistical analysis plan

Time frame: We anticipate final sharing of data will take place at the completion of the 5-year project, but if an interim analysis results in a publication, the dataset will be shared at that time-point.

Access criteria: The data will be publicly available and searchable on figshare (figshare.com), and the availability of shared derived data will be described in publications and presentation.

No publications or documents are linked to this record.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Nov 2029, 35 months later.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 35 months is above that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Dec 2026, last on Nov 18, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 29, 2024
First posted
Jun 4, 2024
StartEst.
Dec 1, 2026was Aug 2026
Primary completionEst.
Nov 30, 2029
CompletionEst.
Mar 1, 2030
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Dec 1, 2026
moved 2 times, Nov 12, 2026 – Nov 18, 2026
Show all 2 updates
  1. Nov 18, 2026
    Start date Nov 1, 2026→Dec 1, 2026
    + 1 other change: verification date
  2. Nov 12, 2026
    Start date Aug 1, 2026→Nov 1, 2026
    + 1 other change: identifiers

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06442631
Responsible party
Christopher Favilla (Assistant Professor of Neurology at the University of Pennsylvania, University of Pennsylvania) — Principal investigator
First posted
Jun 4, 2024
Start date
Dec 1, 2026 (estimated)
Primary completion
Nov 30, 2029 (estimated)
Completion
Mar 1, 2030 (estimated)
Last update
Nov 18, 2026

Study contacts

Christopher G Favilla, MD
Contact
christopher.favilla@pennmedicine.upenn.edu
2156153727
Nichole Gallatti
Contact
nichole.gallatti@pennmedicine.upenn.edu
2153498651
Christopher G Favilla, MD
principal investigator · Assistant Professor of Neurology at the University of Pennsylvania

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion